ASCO Annual Meeting

Cetuximab Works Better than Bevacizumab as Initial Treatment for Advanced Colorectal Cancer

ASCO Annual Meeting
June 1, 2013

According to a recent study, initial treatment with the drug cetuximab (Erbitux) plus the chemotherapy regimen FOLFIRI lengthens the lives of patients with metastatic colorectal cancer when compared with bevacizumab (Avastin) plus FOLFIRI. The chemotherapy regimen FOLFIRI includes the drugs leucovorin (Wellcovorin), fluorouracil (5-FU, Adrucil), and irinotecan (Camptosar).  

New Targeted Therapy for Chronic Lymphocytic Leukemia Shows Promise

ASCO Annual Meeting
May 15, 2013

In early, ongoing research, the drug, idelalisib helped to shrink tumors for patients with recurrent or treatment-resistant chronic lymphocytic leukemia (CLL). CLL is a slow-growing cancer and many patients do not need treatment until they start having symptoms. However, after treatment, most patients will have the disease come back, called recurrent or relapsed CLL. About 20% of patients will develop treatment-resistant or refractory CLL, meaning the disease comes back quickly or the original treatment did not work.

Pages

Subscribe to RSS - ASCO Annual Meeting